Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia.
Yang J et al.
Bioorganic Chemistry, 2025
Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis.
Yang J et al.
Biochemistry and Biophysics Reports, 2025
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.
Yang T et al.
Scientific Reports, 2024
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Joshi SK et al.
American Journal of Hematology, 2023
Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.
Wang Z et al.
Oxidative Medicine and Cellular Longevity, 2022
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.
Ge SS et al.
Frontiers in Oncology, 2022
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Joshi SK et al.
American Journal of Hematology, 2021
Select a paper to view details